摘要
心血管毒性是蒽环类抗生素治疗癌症时的严重并发症。除了嵌入DNA/RNA结构,阻止DNA-拓扑异构酶和组蛋白驱逐染色质,他们行为的主要机制是不同形式自由基的铁介导的形成,引起癌症细胞的不可逆损伤。蒽环类抗生素最严重的负面效应是心肌病(导致充血性心力衰竭),这是由相同的机制造成的。在此,我们简要的总结了由蒽环类抗生素引起的不同种类自由基的基本类型和清楚他们的主要途径。从此中,我们主要关注了金属硫蛋白。本文介绍了这些分子小、富含半胱氨酸的蛋白质,综述了他们的功能与性质。除此之外,我们讨论了他们的金属和药物减毒作用。基于这些有用的作用,他们作为新的抗氧化应激和心血管保护治疗剂的使用被客观的评价(通过与通常使用的细胞抑制剂对比增加耐药性的能力)。
关键词: 蒽环类抗生素,心血管保护,细胞抗氧化应激,化学耐药性,阿霉素,自由基,金属硫蛋白
图形摘要
Current Drug Targets
Title:Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Volume: 17 Issue: 12
Author(s): Zbynek Heger, Miguel Angel Merlos Rodrigo, Sona Krizkova, Branislav Ruttkay-Nedecky, Marta Zalewska, Elena Maria Planells del Pozo, Aurelie Pelfrene, Bertrand Pourrut, Marie Stiborova, Tomas Eckschlager, Gabriella Emri and Rene Kizek and Vojtech Adam
Affiliation:
关键词: 蒽环类抗生素,心血管保护,细胞抗氧化应激,化学耐药性,阿霉素,自由基,金属硫蛋白
摘要: Cardiotoxicity is a serious complication of anticancer therapy by anthracycline antibiotics. Except for intercalation into DNA/RNA structure, inhibition of DNA-topoisomerase and histone eviction from chromatin, the main mechanism of their action is iron-mediated formation of various forms of free radicals, which leads to irreversible damage to cancer cells. The most serious adverse effect of anthracyclines is, thus, cardiomyopathy leading to congestive heart failure, which is caused by the same mechanisms. Here, we briefly summarize the basic types of free radicals formed by anthracyclines and the main processes how to scavenge them. From these, the main attention is paid to metallothioneins. These low-molecular cysteine-rich proteins are introduced and their functions and properties are reviewed. Further, their role in detoxification of metals and drugs is discussed. Based on these beneficial roles, their use as a new therapeutic agent against oxidative stress and for cardioprotection is critically evaluated with respect to their ability to increase chemoresistance against some types of commonly used cytostatics.
Export Options
About this article
Cite this article as:
Zbynek Heger, Miguel Angel Merlos Rodrigo, Sona Krizkova, Branislav Ruttkay-Nedecky, Marta Zalewska , Elena Maria Planells del Pozo, Aurelie Pelfrene, Bertrand Pourrut, Marie Stiborova, Tomas Eckschlager, Gabriella Emri and Rene Kizek and Vojtech Adam , Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?, Current Drug Targets 2016; 17 (12) . https://dx.doi.org/10.2174/1389450116666151001113304
DOI https://dx.doi.org/10.2174/1389450116666151001113304 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Wogonin Alleviates Hyperglycemia Through Increased Glucose Entry into Cells Via AKT/GLUT4 Pathway
Current Pharmaceutical Design Targeting the Chemokines in Cardiac Repair
Current Pharmaceutical Design Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Red Cell Glycolytic Enzyme Disorders Caused by Mutations: An Update
Cardiovascular & Hematological Disorders-Drug Targets Vitamin E in Oxidant Stress-Related Cardiovascular Pathologies: Focus on Experimental Studies
Current Pharmaceutical Design Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Genetic Determinants of Severe Respiratory Syncytial Virus Infection and Post-Bronchiolitis Wheeze: A Systematic Review
Current Respiratory Medicine Reviews The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Current Neuropharmacology Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results
Current Medicinal Chemistry Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology